Matches in DBpedia 2015-04 for { <http://dbpedia.org/resource/Delcath_Systems,_Inc.> ?p ?o }
Showing triples 1 to 38 of
38
with 100 triples per page.
- Delcath_Systems,_Inc. abstract "Delcath Systems, Inc. is a developer of percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion.".
- Delcath_Systems,_Inc. wikiPageExternalLink story?id=6803208&page=1.
- Delcath_Systems,_Inc. wikiPageExternalLink 20070530006062.html?.v=1.
- Delcath_Systems,_Inc. wikiPageExternalLink index.jsp?ndmViewId=news_view&newsId=20070626005495&newsLang=en.
- Delcath_Systems,_Inc. wikiPageExternalLink 4332824-1.html.
- Delcath_Systems,_Inc. wikiPageExternalLink www.delcath.com.
- Delcath_Systems,_Inc. wikiPageExternalLink 071207.asp.
- Delcath_Systems,_Inc. wikiPageExternalLink www.livercancertrials.com.
- Delcath_Systems,_Inc. wikiPageExternalLink 30pati.html?_r=1&scp=4&sq=ocular%20melanoma&st=cse.
- Delcath_Systems,_Inc. wikiPageID "12293417".
- Delcath_Systems,_Inc. wikiPageRevisionID "630665271".
- Delcath_Systems,_Inc. hasPhotoCollection Delcath_Systems,_Inc..
- Delcath_Systems,_Inc. subject Category:Cancer_organizations_based_in_the_United_States.
- Delcath_Systems,_Inc. subject Category:Companies_based_in_New_York_City.
- Delcath_Systems,_Inc. subject Category:Companies_listed_on_NASDAQ.
- Delcath_Systems,_Inc. subject Category:Health_care_companies_of_the_United_States.
- Delcath_Systems,_Inc. subject Category:Hepatology.
- Delcath_Systems,_Inc. type Abstraction100002137.
- Delcath_Systems,_Inc. type CancerOrganizations.
- Delcath_Systems,_Inc. type CompaniesBasedInNewYorkCity.
- Delcath_Systems,_Inc. type Company108058098.
- Delcath_Systems,_Inc. type Group100031264.
- Delcath_Systems,_Inc. type HealthCareCompaniesOfTheUnitedStates.
- Delcath_Systems,_Inc. type Institution108053576.
- Delcath_Systems,_Inc. type Organization108008335.
- Delcath_Systems,_Inc. type SocialGroup107950920.
- Delcath_Systems,_Inc. type YagoLegalActor.
- Delcath_Systems,_Inc. type YagoLegalActorGeo.
- Delcath_Systems,_Inc. type YagoPermanentlyLocatedEntity.
- Delcath_Systems,_Inc. comment "Delcath Systems, Inc. is a developer of percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver.".
- Delcath_Systems,_Inc. label "Delcath Systems, Inc.".
- Delcath_Systems,_Inc. sameAs m.02vz81l.
- Delcath_Systems,_Inc. sameAs Q5253556.
- Delcath_Systems,_Inc. sameAs Q5253556.
- Delcath_Systems,_Inc. sameAs Delcath_Systems,_Inc..
- Delcath_Systems,_Inc. wasDerivedFrom Delcath_Systems,_Inc.?oldid=630665271.
- Delcath_Systems,_Inc. homepage www.delcath.com.
- Delcath_Systems,_Inc. isPrimaryTopicOf Delcath_Systems,_Inc..